CClinicalTrials.gg
Sign In
Not yet recruitingNCT07531472Updated Apr 22, 2026

Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis

An interventional study of Hyaluronic Acid Gel and Petroleum jelly in Epistaxis, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Sex
All
01

Study summary

The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis.

Read the detailed description
  • Epistaxis is one of the most common otorhinolaryngologic emergencies. It affects up to 60% of the population during their lifetime, with 6% requiring medical attention. The greatest peaks in the overall incidence occur in individuals under 10 years of age and over 40 years of age.
  • In 1879, James Little identified an arterial plexus on the anterior septum as a frequent site of bleeding and the same plexus was described one year later by Kiesselbach. As a result of these descriptions, the area most frequently implicated in epistaxis is known as Little's area or Kiesselbach plexus which is anatomically formed by the anastomosis between the terminal branches of the external and internal carotid arteries (Anterior ethmoidal artery, Septal branch of Superior labial artery, Septal branch of Sphenopalatine artery, Septal branch of Greater palatine artery) .
  • The most common etiology of epistaxis is idiopathic in 80%-90% of cases, no precipitating causes can be identified. Of the other identifiable local causes of epistaxis, the most frequent are trauma, nasal neoplasm, iatrogenic or due to systemic factors (hypertension, coagulopathy, inflammatory conditions, infectious diseases, vessel wall fibrosis in associated with ageing), use of drugs (anticoagulant, antiplatelet, nonsteroidal anti-inflammatory nasal sprays) and congenital nasal septal abnormalities .
  • Management of recurrent anterior epistaxis can be done by cautery (chemical or electrical), anterior nasal packing or Surgical therapy if the other methods failed .
  • This protocol outlines standardized guidelines for the use of Hyaluronic Acid (HA) in epistaxis management for nasal mucosal hydration, healing, and recurrence prevention. It is suitable for use in ENT clinics, emergency departments, and hospital wards.

  • Mechanism of action of Hyaluronic acid:

    1. Hydration: Binds large amounts of water, maintaining skin moisture and elasticity.
    2. Wound healing: Promotes keratinocyte and fibroblast proliferation, enhancing tissue repair and regeneration.
    3. Anti-inflammatory effect: Reduces inflammatory cytokines and modulates immune response.
    4. Barrier protection: Forms a protective layer that prevents water loss and protects against irritants and microbes.
    5. Collagen stimulation: Supports collagen synthesis and improves skin structure.
    6. Antioxidant action: Scavenges free radicals, reducing oxidative damage.
02

Conditions studied

  • Epistaxis

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with anterior localized idiopathic epistaxis

Exclusion criteria

Exclusion Criteria:

  • Patients wit secondary epistaxis (posttraumatic, postoperative, tumoral).
  • During pregnancy.
  • Patients wit major systemic disease (Blood Disease, Hypertension).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Hyaluronic Acid Gel

    "Participants in this group will receive topical hyaluronic acid gel applied to the nasal mucosa for the treatment of epistaxis. The application will be done as per the study protocol, and outcomes will be monitored over the study period."

    Drug: Hyaluronic Acid Gel

  • Experimental
    Petroleum Jelly

    "Participants in this group will receive topical petroleum jelly applied to the nasal mucosa for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored over the study period."

    Drug: Petroleum jelly

Interventions

  • DrugHyaluronic Acid Gel

    "Topical hyaluronic acid gel will be applied to the nasal mucosa of participants for the treatment of epistaxis. The gel will be administered according to the study protocol and frequency, and outcomes will be assessed throughout the study period."

  • DrugPetroleum jelly

    "Topical petroleum jelly will be applied to the nasal mucosa of participants for the treatment of epistaxis. The application will follow the study protocol, and outcomes will be monitored and recorded over the study period."

05

What researchers measure

Primary outcomes

  1. To compare the recurrence rate of epistaxis between the two groups

    "Proportion of participants whose epistaxis stops completely within 7 days of treatment application."

    Time frame: 14 days

Secondary outcomes

  1. To assess time to symptom resolution

    "Time in minutes or hours from first application to complete cessation of nasal bleeding."

    Time frame: Within 24 hours

  2. To evaluate mucosal healing (endoscopic findings)

    "Assessment of nasal mucosa healing using endoscopic examination after application of hyaluronic acid gel or petroleum jelly, scored according to a standardized mucosal healing scale."

    Time frame: 7-14 days

  3. To assess patient comfort and compliance

    "Measured using a standardized questionnaire or visual analog scale during the treatment period."

    Time frame: 7 days

  4. To record adverse effects

    "Incidence of local irritation, allergic reactions, or other side effects related to the topical intervention."

    Time frame: 14 days

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07531472
Lead sponsor
Assiut University
Responsible party
Marina Emil Kamal Kaml (Otolaryngology Resident, Assiut University) — Principal investigator
First posted
Apr 15, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Marina Emil Kamal Kaml, M.B.B.CH
Contact
Mareena.20134245@med.aun.edu.eg
+201274047194
Ahmed Ragab Sayed, Lecturer
Contact
ahmedsayed12345@aun.edu.eg
+201099924177
Ahmed AbdelAleem AbdelWahab, Prof
study director

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Epistaxis→

Other studies from this sponsor

Assiut University

Start the discussion